Enabling Screening for All
We are the pioneer in portable eye screening technologies. Our handheld imaging devices and AI services help to improve access to eye screening for blinding eye diseases.
Read more
BREAKING NEWS
FDA clears Optomed Aurora AEYE
Redefine diabetic retinopathy detection with the first FDA-cleared handheld AI fundus camera for the autonomous, on-the-spot detection of diabetic retinopathy.
PUBLICATION
Interim Report 2025
Optomed’s Interim Report January – March 2025 is now published. Read the full report now.
Diabetic retinopathy
The number of diabetics has been growing rapidly around the world and one third of them suffer from diabetic retinopathy, the most common cause of vision loss in working-age adults.
Diabetic retinopathy is treatable, if detected early. However, due to the limited number of ophthalmologists and eye screening services, majority of diabetics globally do not have access to regular screenings.
80%
of what we learn is through our eyes.¹
537
million diabetics worldwide.²
80%
of vision-related problems are preventable and treatable.³
Our solution to a global problem
Effective eye screening prevents diabetes-related blindness and reduces overall health care costs.
We develop innovative and affordable solutions to enable eye screening for all patients worldwide.